
Opinion|Videos|October 15, 2024
Exploring Oral Systemic Therapies For Plaque Psoriasis: Efficacy, Safety, and Clinical Considerations
Lauren Miller, MPAS, PA-C; Jayme M. Heim, MSN FNP-BC, and Kirk Gautier, PA-C, discuss recent advancements in plaque psoriasis treatment, focusing on novel oral systemic therapies like the TYK-2 inhibitor deucravacitinib and its clinical trial data, to inform therapeutic decisions for this systemic disease.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Kidney Compass: VISIONARY 2-Year eGFR Data in IgA Nephropathy
2
Bimekizumab Data Support Case for Earlier Intervention in HS
3
A Genetic Signature May Predict Who Gets Sick From CAR T Cell Therapy
4
Rethinking HFpEF Screening and Care, With Ronald D'Agostino, DO
5








































































